3,336 Shares in Pharvaris (NASDAQ:PHVS) Bought by Cubist Systematic Strategies LLC

Cubist Systematic Strategies LLC bought a new position in Pharvaris (NASDAQ:PHVS) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 3,336 shares of the company’s stock, valued at approximately $64,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. FMR LLC boosted its stake in Pharvaris by 3.6% in the 4th quarter. FMR LLC now owns 5,395,370 shares of the company’s stock worth $103,429,000 after purchasing an additional 189,714 shares during the period. Rock Springs Capital Management LP boosted its stake in Pharvaris by 2.4% in the 4th quarter. Rock Springs Capital Management LP now owns 775,131 shares of the company’s stock worth $14,859,000 after purchasing an additional 18,200 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in Pharvaris by 36.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 443,896 shares of the company’s stock worth $8,510,000 after purchasing an additional 118,408 shares during the period. Northern Trust Corp boosted its stake in shares of Pharvaris by 483.9% during the 4th quarter. Northern Trust Corp now owns 91,932 shares of the company’s stock worth $1,762,000 after buying an additional 76,188 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Pharvaris by 3.7% during the 4th quarter. Geode Capital Management LLC now owns 38,333 shares of the company’s stock worth $735,000 after buying an additional 1,356 shares during the last quarter.

Analyst Ratings Changes

A number of equities analysts have recently commented on PHVS shares. Cantor Fitzgerald reduced their price objective on shares of Pharvaris from $28.00 to $25.00 and set an “overweight” rating for the company in a research note on Wednesday, May 14th. JMP Securities increased their price objective on shares of Pharvaris from $46.00 to $55.00 and gave the stock a “market outperform” rating in a research note on Friday, January 31st.

Pharvaris Price Performance

Pharvaris stock opened at $16.69 on Tuesday. Pharvaris has a one year low of $11.51 and a one year high of $25.50. The company has a market cap of $872.72 million, a price-to-earnings ratio of -5.96 and a beta of -2.85. The firm has a 50-day moving average of $15.39 and a 200-day moving average of $17.53.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.89) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.09). As a group, sell-side analysts expect that Pharvaris will post -2.71 earnings per share for the current year.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.